Hogan Lovells represents Optinose in its US55 million registered direct offering

Hogan Lovells represents Optinose in its US$55 million registered direct offering

Press releases | 28 May 2024

Philadelphia, 28 May 2024 – Global law firm Hogan Lovells guided Optinose, Inc. (NASDAQ:OPTN) in a registered direct offering of approximately US$55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors.

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose, and throat (ENT) and allergy specialists.

In the offering, Optinose sold 31,800,000 shares of its common stock at a price of US$1.00 per share. Optinose also sold to certain investors pre-funded warrants to purchase up to an aggregate of 23,700,000 shares of its common stock at a price of US$0.999 per each pre-funded warrant, which represented the per share offering price for the common stock less the US$0.001 per share exercise price for each such pre-funded warrant.

The Philadelphia-based Hogan Lovells team was led by partners Steve Abrams and Stephen Nicolai, senior associate Amanda Brown, and law clerk Pablo Castiella.